LOG IN
SIGN UP
MARKET
TTNP
TTNP
Titan Pharmaceut
NASDAQ
0.7501
-0.0199
-2.58%
Closed 18:48 03/22 EDT
OPEN
0.7500
PREV CLOSE
0.7700
HIGH
0.7700
LOW
0.7500
VOLUME
14.57K
TURNOVER
--
52 WEEK HIGH
1.590
52 WEEK LOW
0.3496
MARKET CAP
10.97M
P/E (TTM)
-0.8787
1D
5D
1M
3M
1Y
5Y
Theriva Biologics, Research Frontiers And 1 Other Penny Stock Insiders Are Aggressively Buying
Benzinga · 01/27 11:28
BRIEF-Titan Pharmaceuticals Inc-On Jan 4, 2023 Received Notice Of Delisting Or Failure To Satisfy Continued Listing Transfer Of Listing From Nasdaq
Reuters · 01/06 21:20
BRIEF-Titan Pharmaceuticals Provides Shareholder Update
Reuters · 12/15/2022 14:11
Titan Pharmaceuticals Enters Into A Non-binding Letter Of Intent To Complete A Reverse Merger With A Leading Developer In Advanced Air Mobility
Benzinga · 12/15/2022 12:06
Titan Pharmaceuticals Provides Shareholder Update
Signs Non-Binding Letter of Intent for Transformational TransactionContinues to Make Substantial Progress on Strategic Transactions Including Sale of Existing Assets SAN FRANCISCO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP...
GlobeNewswire · 12/15/2022 12:00
Titan Pharmaceuticals Signs Letter of Intent for Reverse Merger; Shares Drop
Titan Pharmaceuticals Signs Letter of Intent for Reverse Merger; Shares Drop
MT Newswires · 12/15/2022 10:52
BRIEF-Update -- Titan Pharmaceuticals Announces Licensing Deal With Ocular Therapeutix
Reuters · 12/12/2022 13:30
Titan Pharmaceuticals Inc. Announces Licensing Agreement With Ocular Therapeutix Inc.
Benzinga · 12/12/2022 11:33
About TTNP
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing therapeutics using its long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. Its ProNeura continuous drug delivery system consists of a small, solid rod-shaped implant made from a mixture of ethylene-vinyl acetate (EVA), and a drug substance. Its product Probuphine (buprenorphine implant), is based on ProNeura technology, which is used for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 milligrams (mg) or less a day of oral buprenorphine. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant and Nalmefene Implant. Its TP-2021 is used for the treatment of moderate-to-severe chronic pruritus. Its Nalmefene Implant is used for the prevention of relapse in opioid use disorder (OUD) patients following detoxification from opioids.
Webull offers kinds of Titan Pharmaceuticals, Inc. stock information, including NASDAQ:TTNP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TTNP stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading TTNP stock methods without spending real money on the virtual paper trading platform.